|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011777,
umls-concept:C0026764,
umls-concept:C0039736,
umls-concept:C0040732,
umls-concept:C0205173,
umls-concept:C0282461,
umls-concept:C0439859,
umls-concept:C0600558,
umls-concept:C1176309,
umls-concept:C1511484,
umls-concept:C1518321,
umls-concept:C1707455
|
|
pubmed:issue |
9758
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:BaccaraniMicheleM,
pubmed-author:CaravitaTommasoT,
pubmed-author:CavoMicheleM,
pubmed-author:CelliniClaudiaC,
pubmed-author:CorradiniPaoloP,
pubmed-author:CrippaClaudiaC,
pubmed-author:DeliliersGiorgio LambertenghiGL,
pubmed-author:Di RaimondoFrancescoF,
pubmed-author:GIMEMA Italian Myeloma Network,
pubmed-author:GalliMonicaM,
pubmed-author:LeddaAntonioA,
pubmed-author:MeugnierMM,
pubmed-author:NarniFrancoF,
pubmed-author:OffidaniMassimoM,
pubmed-author:PalumboAntonioA,
pubmed-author:PantaniLuciaL,
pubmed-author:PescostaNorbertN,
pubmed-author:PetrucciMaria TeresaMT,
pubmed-author:SpadanoAntonioA,
pubmed-author:TacchettiPaolaP,
pubmed-author:TosiPatriziaP,
pubmed-author:ZamagniElenaE
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
18
|
|
pubmed:volume |
376
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2075-85
|
|
pubmed:meshHeading |
pubmed-meshheading:21146205-Adult,
pubmed-meshheading:21146205-Aged,
pubmed-meshheading:21146205-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21146205-Boronic Acids,
pubmed-meshheading:21146205-Chemotherapy, Adjuvant,
pubmed-meshheading:21146205-Dexamethasone,
pubmed-meshheading:21146205-Disease-Free Survival,
pubmed-meshheading:21146205-Drug Administration Schedule,
pubmed-meshheading:21146205-Female,
pubmed-meshheading:21146205-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21146205-Humans,
pubmed-meshheading:21146205-Italy,
pubmed-meshheading:21146205-Kaplan-Meier Estimate,
pubmed-meshheading:21146205-Male,
pubmed-meshheading:21146205-Middle Aged,
pubmed-meshheading:21146205-Multiple Myeloma,
pubmed-meshheading:21146205-Neoadjuvant Therapy,
pubmed-meshheading:21146205-Pyrazines,
pubmed-meshheading:21146205-Remission Induction,
pubmed-meshheading:21146205-Reoperation,
pubmed-meshheading:21146205-Thalidomide,
pubmed-meshheading:21146205-Transplantation, Autologous,
pubmed-meshheading:21146205-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
|
|
pubmed:affiliation |
Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy. michele.cavo@unibo.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
